Scholars@Duke
Journal cover image

Brief Report: Evaluation of Molecular Profiling Strategies for Neoadjuvant Osimertinib in Stage IIIA EGFR-Mutant NSCLC.

Publication ,  Journal Article
Lu, K; Woodward, BD; Boys, J; Onaitis, M; Husain, H
Published in: Clin Lung Cancer
January 2024
Published version (DOI) Link to item

Duke Scholars

Mark William Onaitis
Author Mark William Onaitis Surgery, Cardiovascular and Thoracic Surgery
Altmetric Attention Stats
Dimensions Citation Stats

Published In

Clin Lung Cancer

DOI

10.1016/j.cllc.2023.08.012

EISSN

1938-0690

Publication Date

January 2024

Volume

25

Issue

1

Start / End Page

e58 / e61

Location

United States

Related Subject Headings

  • Pyrimidines
  • Protein Kinase Inhibitors
  • Oncology & Carcinogenesis
  • Neoadjuvant Therapy
  • Mutation
  • Lung Neoplasms
  • Indoles
  • Humans
  • ErbB Receptors
  • Carcinoma, Non-Small-Cell Lung
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Lu, K., Woodward, B. D., Boys, J., Onaitis, M., & Husain, H. (2024). Brief Report: Evaluation of Molecular Profiling Strategies for Neoadjuvant Osimertinib in Stage IIIA EGFR-Mutant NSCLC. Clin Lung Cancer, 25(1), e58–e61. https://doi.org/10.1016/j.cllc.2023.08.012
Lu, Kevin, Brian D. Woodward, Joshua Boys, Mark Onaitis, and Hatim Husain. “Brief Report: Evaluation of Molecular Profiling Strategies for Neoadjuvant Osimertinib in Stage IIIA EGFR-Mutant NSCLC.” Clin Lung Cancer 25, no. 1 (January 2024): e58–61. https://doi.org/10.1016/j.cllc.2023.08.012.
Lu K, Woodward BD, Boys J, Onaitis M, Husain H. Brief Report: Evaluation of Molecular Profiling Strategies for Neoadjuvant Osimertinib in Stage IIIA EGFR-Mutant NSCLC. Clin Lung Cancer. 2024 Jan;25(1):e58–61.
Lu, Kevin, et al. “Brief Report: Evaluation of Molecular Profiling Strategies for Neoadjuvant Osimertinib in Stage IIIA EGFR-Mutant NSCLC.” Clin Lung Cancer, vol. 25, no. 1, Jan. 2024, pp. e58–61. Pubmed, doi:10.1016/j.cllc.2023.08.012.
Lu K, Woodward BD, Boys J, Onaitis M, Husain H. Brief Report: Evaluation of Molecular Profiling Strategies for Neoadjuvant Osimertinib in Stage IIIA EGFR-Mutant NSCLC. Clin Lung Cancer. 2024 Jan;25(1):e58–e61.
Journal cover image

Published In

Clin Lung Cancer

DOI

10.1016/j.cllc.2023.08.012

EISSN

1938-0690

Publication Date

January 2024

Volume

25

Issue

1

Start / End Page

e58 / e61

Location

United States

Related Subject Headings

  • Pyrimidines
  • Protein Kinase Inhibitors
  • Oncology & Carcinogenesis
  • Neoadjuvant Therapy
  • Mutation
  • Lung Neoplasms
  • Indoles
  • Humans
  • ErbB Receptors
  • Carcinoma, Non-Small-Cell Lung